Bioceros

GenScript | June 03, 2020

GenScript Biotech Corp., the world's leading research reagent provider, announced today that the company has filed for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration (FDA) to market its cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit. This is the first test submitted for regulatory approval that specifically detects neutralizing antibodies to SARS-CoV-2, the virus that causes COV-19, without the use of live virus. Current serological antibody tests...

Medical

Bio Detection K9 | May 19, 2022

Bio Detection K9 (BDK9) is pleased to announce its upcoming detection service for Leafroll and Red Blotch Virus in grapes. Of the 86 different viruses known to infect vineyards, Leafroll 3 and Red Blotch virus are among the most prevalent. These pathogens can infect all wine, table and rootstock grapes. They occur in grape production areas around the world and are responsible for causing over 70 billion dollars of damage in the United States alone. To combat these insidious diseas...

Medical

businesswire | September 21, 2023

AbCellera announced that it has expanded its existing multi-target collaboration with Regeneron to discover therapeutic antibodies for up to eight targets selected by Regeneron, increased from the original four. “Having successfully delivered on two challenging discovery campaigns under the original agreement, we are excited to expand the scope of our collaboration with Regenero...

Stemcyte | March 23, 2022

On January 7th, 2022, the FDA received the BLA (Biologics License Application) for the "HPC-Cord Blood" product. On March 8th, 2022, StemCyte was formally informed that the submission was acceptable to join the biologics license quality review process. The "HPC-Cord Blood" is an umbilical cord blood hematopoietic stem cell product intended for unrelated donor hematopoietic progenitor cell transplantation procedures in patients with hematopoietic system disorder...